Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KI-1128
- Development stage
- Preclinical
- Lead developer
- Kuhnil Pharmaceutical
- Modality
- Small Molecules
01
Overview
KI-1128 is an investigational drug candidate being developed by the South Korean firm Kuhnil Pharmaceutical for the treatment of female hypoactive sexual desire disorder (HSDD). Currently in the early research or preclinical stages of development, the drug is part of a pipeline that includes several 'KI' designated candidates for metabolic and central nervous system disorders. Specific details regarding the drug's chemical structure, modality, and exact pharmacological target remain proprietary and have not been disclosed in public clinical or regulatory databases. The project represents Kuhnil's expansion into the therapeutic area of female sexual dysfunction.
Beyond the preview
Go deeper on KI-1128.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KI-1128.